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Abstract
Proteins exhibiting anticancer activities, especially those capable of discriminately killing cancer 
cells, have attracted increasing interest in developing protein-based anticancer therapeutics. This 
progress report surveys recent advances in delivering anticancer proteins directly to tumor tissue 
for inducing apoptosis/necrosis or indirectly to antigen presenting cells for provoking immune 
responses. Protein delivery carriers such as inorganic particles, lipid particles, polymeric particles, 
DNA/protein based biomacromolecular particles as well as cell based carriers are reviewed with 
comments on their advantages and limitations. Future challenges and opportunities are also 
discussed.
Graphical Abstract
This progress report surveys recent advances in the development of micro-/ nanoparticles for 
delivering anticancer proteins to target cellular locus. Numerous types of proteins with anticancer 
activities and their relevant formulations, including inorganic materials, lipids, polymers, 
biomacromolecules and cells were summarized. Challenges and opportunities in this area were 
also discussed.
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Cancer, the leading cause of death in the world, engendered over 10 million new cases each 
year.[1] Current therapies for cancer include surgery, radiation and chemotherapy, but they 
lack selectivity and cause severe damages to normal cells. Chemotherapy also suffers from 
severe multidrug resistance, repeated treatments enable tumors not only resistant to the 
chemotherapeutic agent used but also to agents belonging to the same family or even 
unrelated agents.[2, 3] In contrast, protein therapy shows highly specific set of functions and 
gained increasing use in clinical applications.[4] Proteins play important roles in all stages of 
cancer development by influencing cell morphology, adhesion, migration, cell-cell fusion 
and cancer-inducing virus invasion. Regulating protein activities can effectively affect tumor 
initiation, promotion and progression.[5] Proteins that regulate tumor cell life cycle can 
specifically inhibit tumor progression with minimal damage to normal cells.
Numerous proteins, such as cytokines, enzymes, antibodies and transcription factors have 
demonstrated anticancer activities[6, 7] and their action mechanisms can be classified into 
two categories: activating apoptosis signaling pathway or blocking growth signals.[8, 9] For 
example, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a cytokine 
released by normal cells and binds to the death receptors of tumor cells to initiate extrinsic 
apoptosis pathway.[10, 11] Cytochrome c is released from mitochondrion and initiates the 
intrinsic apoptosis pathway by activating caspases.[11, 12] The caspases are a family of 
proteases in the cytosol and they are the executioner of apoptosis signaling pathway that 
cleave protein substrates, leading to the characteristic apoptosis morphology.[13] Nucleases, 
such as DNAse I, that degrade DNA during apoptosis are also potent therapeutics against 
cancer.[14] Antibodies can kill cancer cells by specifically targeting oncogenic proteins or 
survival factors on tumor cell surface. For examples, CD20 antibody rituximab can ligate 
CD20 on B-cell surface and activate apoptosis signaling[15]; antagonists towards tyrosine 
kinases epidermal growth factor receptor (EGFR) and HER2 can block tumor proliferation 
activities.[16] Tumor suppressor p53 is a transcription factor that induces cell cycle arrest, 
apoptosis and senescence. While frequently mutated in cancer cells, its function can be 
restored by delivering wild type p53 into cancer cells.[17] Besides human derived proteins, 
some proteins derived from non-human sources also exhibit effective and selective cancer 
killing capability. For example, apoptin, a chicken anemia virus derived protein, can target to 
human tumor cell nucleus and induce apoptosis while remain in normal cell cytosome and 
exhibit no cytotoxicity.[18, 19] Asparaginase from Escherichia coli or Erwinia chrysanthemi 
is an enzyme that can deplete its substrate L-asparagine, an non-essential amino acid for 
most normal cells but essential for acute lymphoblastic leukemia cells, to arrest protein 
synthesis in leukemia cells and cause cell death.[20] Besides directly targeting tumor cells, 
proteins can also work as antigens to activate leukocytes, like T-cell, to treat cancer. After 
being phagocytized by antigen-presenting cell (APC), like dendritic cells, the protein 
antigens are processed and presented on APC cell surface to generate an antigen-specific 
cytotoxic T-lymphocytes (CTLs) response.[21, 22] CTLs are capable of recognizing tumor 
cells and inducing apoptosis.[23] Antigens like ovalbumin (OVA),[21, 23, 24] heat-shock 
proteins,[25] and interleukin-4/-12[26, 27] et al. were widely applied as antigenic protein in 
many formulations.
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However, delivering protein is hampered by the intrinsic drawbacks of proteins, such as 
instability, large size and surface charges.[6] The delicate tertiary structures of proteins are 
easily denatured upon exposure to elevated temperatures and the peptide chains are 
susceptible to proteolytic or chemical degradations. Proteins losing activities often cause 
unexpected immune responses.[28] The large size of proteins prevented them from diffusing 
through plasma membrane and the electrostatic repulsion between most negatively charged 
proteins and cell membranes under physiological conditions further reduced protein 
uptake.[29]
Since the first FDA approved protein delivery therapy, PEGylated adenosine deaminase in 
1990, nanocarriers for protein delivery developed rapidly in the last two decades.[30] The 
carriers include inorganic nanocarrers, lipid-based nanocarriers, polymeric nanocarriers, 
biomacromolecule based nanocarriers[6] as well as natural carriers like bacteria[31] and 
human cells[32-34] (Figure 1). The protein cargos can be loaded into the vectors either by 
covalent conjugation via chemical modification, peptide fusion via genetic recombination, 
physical adsorption through electrostatic/hydrophobic interactions or encapsulation via 
polymeric crosslinking.[6] Nanocarriers shield proteins from the denaturing biological 
environment and increase the circulation time of the cargo protein. Unique properties of 
tumor environment are the foundation for designing efficient protein delivery nanoparticles. 
When tumor size reaches >2 mm3, increasing hypoxia of the local environment up-regulates 
the expression of pro-angiogenic proteins. New blood vessels will grow out of existing ones, 
namely angiogenesis, and blood vessels around tumor are aberrant in pericyte and basement 
membrane formation, leading to an enhanced permeability to particles within size range 
20-200 nm. With the absence of lymphatic vessels, nanoparticles enter tumor tissue are 
retained. This phenomenon is named “Enhanced Permeability and Retention (EPR) effect”. 
In addition, extracellular pH of tumor environment is slightly more acidic (pH 6.0-7.0) than 
normal tissue (pH 7.4), the differences in vasculature and pH of tumor environment have 
been widely utilized to design nanocarriers.[35] Targeting tumor tissues can be achieved 
either by passive targeting utilizing the EPR effect or by active targeting with conjugated 
ligands to bind receptors on target cells.[1] After nanocarrier accumulation in tumor tissue, 
efficient intra-cellular protein delivery also require efficient cellular uptake and 
endolysosomal escape. Delivery efficacy of the nanocarriers can be fine-tuned by adjusting 
particle size and surface properties.[37] After reaching the target locus, the cargo protein can 
be released either by passive diffusion or degradation of the nanocarrier.[30] By 
incorporating stimuli responsive moieties, like hydrolytically cleavable or photolabile 
linkers, into the nanocarreirs, spatial-, temporal- and dosage-controlled anticancer protein 
delivery can be achieved.[38]
Unlike nanoparticles that can be administered systematically for cancer targeting, micro-
scaled polymeric particles easily clog capillaries, limiting their intravenous applications.[39] 
Thus, polymeric microparticles are generally administered locally at tumor site by 
subcutaneous injection for prolonged protein drug release.[40, 41] Despite the micro-scaled 
size of cell based microparticles, cell carriers like red blood cells are highly flexible and can 
circulate in the system for ~120 days to target reticuloendothelial system without clogging 
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the capillaries.[42] Properties like natural tropism, surface presented markers and high drug 
loading capacity render cellular carriers promising for protein delivery.[43]
In this progress report, we summarize recent advances in the design of micro-/nanocarriers 
for anticancer protein delivery. Advantages and limitations of currents particles as well as 
future opportunities and challenges are also discussed.
2. Inorganic nanocarriers for anticancer protein delivery
Inorganic carriers, such as calcium phosphate, carbon nanotube, graphene oxide, 
mesoporous silica nanoparticle and gold nanoparticle have been widely applied in drug 
delivery.[44] The core of inorganic nanoparticles retain their opticophysical[45] properties, 
making it suitable for formulating combined therapies or stimuli-responsive drug delivery 
systems.
2.1 Calcium phosphate nanoparticles
Calcium phosphate (CP) nanoparticle is a promising drug carrier for its high 
biocompatibility. It can be dissolved in endosome after cellular uptake into Ca2+ and PO43−, 
which are main components of teeth and bones. Their size can be controlled by using 
different stabilizing agents.[46] Wu et al. used pyridoxial-5’ phosphate functionalized CP 
nanoparticle to load RNAse (13.7 KDa) and asparaginase (150 KDa) via a pH sensitive 
aldimine linker between lysine residues of the protein and pyridoxial-5’ phosphate. The 
carriers successfully delivered cargo proteins of different sizes into the cytosol of HeLa, 
HepG2 and L929 cells.[47] To develop orally administered anticancer drug, Kanwar et al. 
encapsulate lactoferrin, an anticancer protein derived from mammalinan milk, in CP 
nanoparticle. The lactoferrin loaded CP nanoparticle was further coated with alginate and 
chitosan to protect it from gastrointestinal tract degradation. The ~344 nm particle composed 
of a polymeric shell and an inorganic core transported the cargo protein across gut and 
mucosal surfaces into blood circulation and targeted it passively into human colon cancer 
cells in a Caco-2 xenografted mouse model.[48] CP nanoparticle was also developed for 
transcutaneous delivery of antigen by Perumal and coworkers.[49] Besides being the carrier, 
CP nanoparticle works as a vaccine adjuvant to enhance immuno-response as well. 
Negatively charged OVA and another vaccine adjuvant cellobiose were loaded onto the 
positively charged CP nanoparticle by adsorption. In a Balb/C mouse model with stratum 
corneum removed by tape-stripping, CP nanoparticle delivered OVA significantly enhanced 
the antibody titers.
2.2 carbon nanotubes
Carbon nanotubes (CNTs) are cylinders composed of single or multiple layers of graphene 
with carbon atoms bonded in hexagonal lattices.[50] Insolubility and cytotoxicity of pristine 
CNT hinder its biomedical application, which can be alleviated by functionalization. By 
functionalizing single wall carbon nanotube (SWCN) with poly (lactic-co-glycolic) acid 
(PLGA) to achieve high solubility and low cytotoxicity, Cheng et al. used PLGA-SWCN as 
a carrier to deliver caspase-3 into osteosarcoma cell MG-63. PLGA was degraded 
enzymatically after cellular internalization and released the conjugated caspase-3.[51] In 
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addition to polymers, proteins can be adsorbed onto CNT surfaces through van der Waals 
interactions and hydrophobic interactions to improve dispersability and bio-compatibility of 
CNTs.[52, 53] By adsorbing toxin ricin A chain protein (RTA) and a HER2 antibody non-
covalently on multi-walled carbon nanotubes (MWNTs), Weng et al. selectively targeted 
HER2 receptors on specific breast cancer cells and delivered RTA to its natural intracellular 
locus to inhibit protein synthesis. [54] Further investigation of the uptake pathways in HeLa 
cells by tracking the a EGFP tag fused to RTA showed MWNT-RTA was internalized mainly 
through clathrin-mediated endocytosis (Figure 2).[55]
2.3 Graphene oxide nanosheets
Graphene is a 2-D material made of a single layer of carbon atoms, which were attached to 
each other by strong sp2 hybridized carbon-carbon bond[56] The highly reactive surface of 
graphene makes it difficult to be suspended in solution, which can be overcome by oxidizing 
graphene into graphene oxide (GO). The oxidized portion of the surface offers functional 
groups for further conjugation and the un-modified part of the surface is capable of loading 
drugs through hydrophobic interactions and π–π stacking.[57] By conjugating six-armed 
poly-ethylene glycol (PEG) to the carboxyl groups of GO, Shen et al. improved the stability 
and biocompatibility of GO and used the PEG-GO as carrier for delivering RNase A and 
protein kinase A (PKA) to induce cell death and growth, respectively.[58] The RNAse A and 
PKA were loaded via π–π interactions between GO and proteins. Large surface area of GO 
leads to high loading capacity and the carrier also protected the proteins from proteolytic 
degradation. The cargo proteins were released via passive diffusion in a temperature 
dependent manner and intracellularly delivered proteins escaped endosomes and 
accumulated in the cytosol of HeLa cells. However, for the carbon based nanocarriers (CNT 
or graphene), a debate remained regarding the toxicity of these carriers that may hinder the 
application of these nanoparticles.[59]
2.4 Mesoporous silica nanoparticles
Mesoporous silica nanoparticles (MSNs) are mono-dispersed nanoparticles with controllable 
size and mesostructure.[60] MSNs have been widely used in delivering drugs and proteins for 
its ease of synthesis, versatile surface functionalization, high bio-compatibility and stability. 
Protein release can be controlled by tuning the size, shape and surface functionalization of 
MSN.[61] Mahony et al. modified MCM-41 mesoporous nanoparticle surface with amine 
(AM-41), which reversed the zeta-potential of the particle from negative to positive.[60] 
Positively charged amine modification increased OVA loading capacity of MCM-41 by 2.5-
fold through electrostatic interaction. 7.9% of AM-41 loaded OVA were released within 30 
min through passive diffusion. Besides being a carrier, the MSN also works as an adjuvant 
and elicited immune response at low OVA concentration. In addition to loading proteins by 
electrostatic interaction into MSNs, Gu et al. loaded cytochrome c into the channels of large 
pore-MSN by controlling the pore size of MSN with N,N-dimethylhexadecylamine.[62] To 
achieve controlled release of cytochrome c from MSN pores, Meńdez et al. conjugated 
cytochrome c covalently into SH-functionalized MSN (MSN-SH) via disulfide bonds[63]. 
Cytochrome c was glycosylated with activated lactose (Lac4) at lysine residues with a ratio 
of lactose/protein around 4/1 to increase the structural stability of cytochrome c during 
immobilization. The glycosylation protected cytochrome c from conformational disruptions 
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caused by the hydrophobic disulfide bond linker (SPDP) and it also prevented the modified 
cytochrome c from proteolytic degradation. The redox responsive release profile of 
cytochrome c from MSN-SH indicated 80% of the loaded cytochrome c was immobilized by 
covalent bonds. Confocal laser scanning microscope confirmed the redox responsive MSN-
SPDP-Cyt c-Lac4 was internalized into HeLa cells and it can escape the endosome to release 
cytochrome c into cytosol.
2.5 Gold nanoparticles
Gold nanoparticle has been widely applied in protein delivery due to its unique 
spectroscopic properties, ease of size control and facile surface functionalization.[64] Tang et 
al. utilized a peptide modified gold nanoparticles (HKRK-AuNP) as a stabilizer in the 
preparation of emulsion based nanoparticles (size 130-140 nm). Negatively charged 
anticancer protein caspase 3 was assembled onto the surface of the AuNP decorated 
nanoparticle, which contains an oil core for facilitated membrane fusion based protein 
delivery (Figure 3).[65] Ahn et al. utilized the immune adjuvant effect of AuNP to develop a 
vaccine for cancer immuno-therapy.[66] A tumor-associated antigen extra domain B (EDB) 
of fibronectin was loaded into AuNP to treat EDB-expressing tumors. Two cysteine residues 
were introduced into the N-terminus of EDB for conjugating EDB-OVA257-269 into gold 
nanoparticle by Au-S bond. The conjugation increased the size of gold nanoparticle from 
11.2 nm to 20 nm. AuNP conjugated EDB-OVA257-269 induced 3-fold higher release of IFN-
γ in dendritic cells and two fold higher release of IL-2 in OT-1 T cells than free EDB-
OVA257-269. In vivo test in a footpad of BALB/c mice showed the injected AuNP-EDB-
OVA257-269 were drained into lymph node and phagocytosed by lymph node resident 
dendritic cells, generating antigen-specific antibody. In a mouse model bearing a EDB-over 
expressing tumor 4T1, tumor growth was substantially inhibited by AuNP-EDB-OVA257-269 
(46%) than the free antigen (86%) and saline (100%). In addition to conjugating protein 
antigens onto AuNP covalently, AuNP can deliver protein without chemical interactions 
between the protein and AuNP. Due to its lipid-fluidizing capability, gold nanoparticle 
smaller than 10 nm is permeable to the skin, which can be utilized to deliver protein into 
deep skin layers.[67] Huang et al. synthesized 5 nm gold nanoparticle and tested its ability to 
deliver proteins percutaneously by co-administering the proteins with gold nanoparticle. 
Topical application of the gold nanoparticle transiently created openings in the skin, 
allowing the co-administered protein to penetrate. OVA was chosen as a model protein and 
its immune responses were tested in a Balb/c mouse model. The mixture of OVA and gold 
nanoparticle was highly immunogenic and generated anti-OVA IgG gradually over the time 
of immunization. In stead of utilizing the size of gold nanoparticles, Tang et al. utilized the 
photo-thermal properties of gold nanorod to ablate hydrophobic stratum corneum barrier of 
the skin and incubate OVA solution with the treated skin to deliver OVA.[68] The 
longitudinal surface plasma resonance of electrons in gold nanorod can be applied in photo-
thermal therapy, which absorbs near-infrared light (NIR) between 800-900 nm. In the 
optimum NIR condition, continuous wave lasers at 150 mW increased skin temperature to 
45 °C without denaturing skin surface proteins and translocated OVA efficiently into the 
skin. In vivo test showed that the OVA translocation efficiency by photothermal ablation of 
gold nanorod is comparable to that using a solid in oil dispersion. In addition, 
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immunochemistry analysis indicated that the phothothermal treatment of the skin also 
induced HSP 70 expession.
3. Lipid based carriers for anticancer protein delivery
3.1 Liposome
Liposomes are closed phospholipid bilayers containing an aqueous core, which can load 
water soluble drugs. Size of liposomes can be fine controlled by techniques like sonication, 
homogenization, extrusion or microfluidic mixing.[69] Modification of lipid components or 
surface of liposomes with different functional moieties enable facile surface modification of 
liposomes for desired drug loading and release properties. Yuba et al. developed a pH 
responsive liposome to deliver OVA.[24] Carboxylated poly(glycidol)s, pH sensitive 
polymers with high fusogenic properties, were synthesized and conjugated to the top of the 
head group of egg yolk phosphatidylcholine liposomes to introduce pH responsive 
fusognenic properties while avoid disrupting the stability of liposome. The carboxylate 
anion of the polymer enhanced liposome uptake by dendritic cell 2.4 by at least 5 fold and 
released OVA into dendritic cell cytosol to generate antigen-specific cytotoxic T 
lymphocyte. Mice immunized with the pH responsive fusogenic liposome containing OVA 
completely rejected OVA-expressing E.G7-OVA cells and achieved regression of E.G7-OVA 
tumors.
In addition to loading proteins in the aqueous core of liposomes, surface of liposomes can 
also be modified for protein loading. Sarker et al. explored the strategy of adsorbing 
negatively charged proteins to positively charged liposomes for functional protein 
delivery.[70] The synthetic lysine based cationic aminolipid with a trifluoroacetic acid 
counterion in the head group assembled into bilayered liposome with a size of 96 ± 40 nm 
and zeta potential of +60 mV at pH 7.4. Complexation of the positively charged liposome 
with the negatively charged proteins was achieved by mixing. They found that fetus bovine 
serum (FBS) proteins in the culture media readily exchanged with bovine serum albumin 
(BSA) adsorbed on liposome surface, and protein release rate is positively correlated with 
lipid content in the complex. Uptake and intracellular trafficking analysis showed that the 
uptake of the complex in HeLa cells is energy dependent and the complex can escape 
endosome entrapment after 24 h of incubation. Utilizing Ni2+-His tag chelation, Miguel et 
al. incorporated a lipid nickel salt DOGS-NTA-Ni into liposome to tether TRAIL-His10 onto 
liposome surface and obtained particles with z-average size of 178 ± 85.3 nm.[71] TRAIL 
bound to liposome surface increased the anticancer activity of free TRAIL in Jurkat 
leukemia T-cells by reducing the LC50 by around 14-fold. Using protein conjugated lipid 
component, Seifert et al. inserted anti-EGFR single-chain Fv fragment conjugated lipid with 
TRAIL conjugated lipid into a PEGylated liposome and enhanced the liposome's targeting 
efficiency towards EGFR-expressing Colo205 cells. Adding anti-EGFR single-chain Fv 
fragment reduced the EC50 of TRAIL loaded liposome from 20.2 ± 0.8 to 8.0 ± 0.4μM 
lipid.[72] Similarly, lipid particles without the aqueous core are also efficient carriers for 
intracellular protein delivery. For example, Kim et al. loaded cytochrome c via a conjugated 
lipophilic peptide into a 20-30 nm lipid nanodisc composed of lipid and apolipoprotein to 
induce apoptosis in H460 cells.[73] Wang et al. modified RNAse A or saporin with an acid-
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labile cis-aconitic anhydride to make the protein surfaces negatively charged. The synthetic 
cationic lipids readily complexed with the modified protein through electrostatic interactions 
and formed ~130 nm nanoparticles.[74] The lipid-protein complex, but not protein or lipid 
alone, exhibited significant cytotoxicity towards B16F10 murine melanoma cancer cells.
Besides delivering protein as mono-therapy, liposome has been successfully applied in 
combination therapy for delivering a therapeutic protein together with a small molecule 
drug. Guo et al. encapsulated TRAIL and Doxorubicin (DOX) in the aqueous core of two 
liposomes, separately.[75] The delivered DOX selectively sensitized brain tumor 
glioblastoma multiforme (GBM) cells to TRAIL induced apoptosis by up-regulating DR5 
and caspases −3, −8, −9 expression.[76] Instead of loading TRAIL and DOX in two separate 
liposome, Jiang et al. used a strategy to deliver TRAIL and DOX in one single polymeric gel 
coated liposome particle (Gelipo).[10] DOX is encapsulated in the aqueous core of a cell 
penetrating peptide modified liposome while TRAIL is adsorbed onto the hyaluronic acid 
(HA) shell via electrostatic interaction (Figure 4). The HA shell functions as a targeting 
ligand, which binds CD44 receptor of a variety of tumor cells, as well as a stimuli 
responsive element that can be degraded by hyaluronidase (HAase) rich in tumor 
environment. This strategy achieved sequential delivery of different cargos to different 
locations of the tumor cell. The TRAIL-DOX-Gelipo with a size of 110 nm accumulates at 
the tumor environment by both passive and active targeting. HAase at the tumor 
environment degraded the HA shell and released TRAIL to target death receptors on cell 
surface, the cell penetrating peptide on the remaining liposome surface then induced 
internalization of the DOX loaded liposome and delivered DOX intracellularly to cell nuclei. 
In vitro study showed that 80 % of the loaded TRAIL bound to cell surface in the presence 
of HAase and the presence of TRAIL on the outer-membrane of DOX-Gelipo reduced its 
IC50 towards MDA-MB-231 cell from 569 ng mL−1 to 83 ng mL−1 (in DOX concentration). 
In vivo study in a xenograft mouse model with implanted MDA-MB-231 tumors, Cy5.5 
labeled TRAIL-Gelipo showed higher fluorescence signal at tumor site than normal tissue 
48 h after injection, validating efficient tumor-targeting efficiency of this formulation.
3.2 Cell derived exosome/vesicles
In contrast with liposomes, which are biomimetic bi-layered lipid nanoparticle, cell derived 
exosomes or vesicles are the natural counterpart of liposome with huge potential in drug 
delivery.[77] These extracellular vesicles, with size ranging form 20 to 2000 nm, played 
important role in intercellular communication by transferring signaling molecules. Since 
exosomes are derived from endolysosomal pathway and vesicles are generating by budding 
from cell membrane, protein compositions on these microvesicle membranes are influenced 
by their parent cell lines.[78] Gehrmann et al. developed an anticancer immunotherapy by 
loading OVA and a glycolipid antigen α-galactosylceramide (αGC) into a dendritic cell 
derived exosome.[79] Supernatant of mouse bone marrow dendritic cell cultures pretreated 
with OVA, T-cell OVA-specific peptide SIINFEKL and/or αGC were used for exosome 
preparation by filtering through a 0.22-μm cut-off filter. While free αGC triggers invariant 
NKT (iNKT) anergy, αGC loaded in exosomes can activate iNKT cells, leading to the 
activation of NK and γδ T cells with important anticancer activity, including OVA-specific 
CD8+ T cells. In a mouse model with an OVA expressing melanoma, OVA/αGC loaded 
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exosome activated adaptive immunity without triggering iNKT cell anergy and decreased 
tumor growth. Similarly, Tian et al. challenged dendritic cells with exsosomes secreted from 
melanoma B16 and Lewis lung carcinoma (LLC) to present antigens and prepared 
exsosomes from these dendritic cells. The B16 and LLC antigen presenting exosomes 
effectively activated cytotoxic T lymphocytes and 70% and 87.5% of the immunized mice 
were tumor free at 30 days after B16 cell and LLC cell challenge, respectively.[80] To deliver 
proteins for anticancer pro-drug activation, Mizrak et al. expressed the protein/mRNA of a 
genetically fused protein CD-UPRT (cytosine deaminase fused with uracil 
phosphoribosyltransferase) in a donor HEK-293T cell, which can activate the co-
administered pro-drug 5-fluorocytosine (5-FU) to its toxic form 5-fluoro-deoxyuridine 
monophos-phate (5-FdUMP) that can inhibit DNA synthesis.[81] Vesicles containing CD-
UPRT protein/mRNA was harvested from the donor cell medium by differential 
centrifugation, ultracentrifugation, and filtration. Vesicles containing protein/mRNA of CD-
UPRT was injected into a mouse model with pre-established nerve sheath tumors 
(schwannomas) followed by intraperitoneally administered 5-FC, the tumor growth was 
completely inhibited in 6 out of 9 mice.
4. Polymeric nanocarriers for anticancer protein delivery
4.1 Polymer-protein Conjugation
Covalent attachment of polymers, such as poly(ethylene glycol) (PEG), on protein surface is 
a facile and efficient strategy in delivering therapeutic proteins. The polymeric shell can 
shield the protein from its antigenic and immunogenic epitopes, protect it from phagocytosis 
or proteolytic degradation. By functionalizing PEG with specific functional groups at its 
terminal, PEG chains can be conjugated to reactive site groups, such as amine, thiol, 
caroboxyl or hydroxyl groups, on the protein surface.[82] With increased circulation lifetime 
and decreased dosage, many PEGylated protein therapeutics, such as enzymes, cytokines, 
antibodies and growth factors, were approved by FDA.[83] By conjugating PEG to protein 
surface lysine (NH2) via a thioester, Chen et al. desinged a reversible protein PEGylation 
process in which the conjugated PEG can be removed at reducing environment.[84] 
Reactivity of the thioester can be modulated by changing the steric environment around the 
thioester to fit the glutathione (GSH) concentration difference between the intracellular 
environment (1-11 mM) and extracellular environment (2–10 μM). Using TRAIL as a model 
protein, PEGylated TRAIL showed reduced toxicity towards Jurkat acute T cell leukemia 
cell line but the toxicity was restored after removing PEG with GSH.
In addition to PEG, many other polymers have been applied in protein conjugation. For 
example, Murata et al. conjugated the cationic polymer polyethylenimine (PEI) to p53 via 
reversible disulfide bonds for enhanced endocytosis into cells through electrostatic 
interactions between the cationized protein and negatively charged cell membranes.[85] E. 
coli expressed p53 readily aggregated into inactive inclusion bodies, which was solubilized 
by PEI modification. The cationized p53 was internalized by Saos-2 cells in denatured form 
and refolded into active tetramers after entering the reductive intracellular environment, 
upregulating p53 targeted protein p21/waf1 to induce apoptosis. Keefe et al. utilized a 
zwitterionic polymer poly(carboxybetaine) (pCB) to conjugate a model protein α-
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chymotrypsin.[86] Zwitterionic polymers are polyelectrolytes that can pose a strong ionic 
interaction with water via their positively and negatively charged groups. Unlike PEG, 
increase in protein stability is not related with pCB molecular weight or the number of pCB 
chains per protein. Without posing a PEG like steric hindrance between substrate and its 
binding pocket, the attachment of pCB drew water away from the protein hydrophobic 
center, allowing substrate to interact with its binding site. Ding et al. applied polymalic acid 
(PMLA), a natural polymer synthesized by Physarum polycephalum as a carrier for 
anticancer protein delivery.[87] A recombinant protein that fused cytokine interleukin-2 
(IL-2) with an antibody specific for human HER2/neu was conjugated to PMLA. They 
demonstrated that the nanobioconjugate is capable of retaining the biological activity of IL-2 
and target HER2/neu-positive tumor cells to inhibit their growth.
4.2 Crosslinking based encapsulation
In solution based polymerization, free proteins were dissolved with monomers or polymers 
in the same solution, into which the addition of cross-linkers and/or initiators lead to the 
encapsulation of proteins in polymeric nanogels. Gu et al. encapsulated caspase-3 in a 
cocoon like polymeric capsule non-covalently by in situ polymerization on the surface of 
caspase-3 (Figure 5).[88] Monomers, such as acrylamide (AAm) and N-(3-aminopropyl) 
methacrylamide (APMAAm), together with a cross-linker adsorbs onto protein surface via 
electrostatic interactions or van der Waals force, the addition of radical initiators into the 
monomer-protein solution starts the polymerization immediately. At the molar ratio of 
protein/AAm at 1200, size of capase-3 increased 5 nm to 13 nm after the encapsulation. The 
positively charged monomer APMAAm reversed the surface charge of caspase-3 from 
negative to positive for efficient cell penetration. By tuning the property of the cross-linker, 
protein release behavior can be controlled. Using a bisacrylated cross-linker that contains the 
substrate peptide of caspase-3 (VDEVDTK), a self-degradable protein nanocapsule was 
obtained. With a non-degradable cross-linker as control, the researchers demonstrated that 
the degradable capsule induced HeLa cell apoptosis within 24 h while no sign of apoptosis 
was observed with naked caspase-3 or caspase-3 encapsulated with non-degradable cross-
linker. To control the degradation process spatiotemporally, the researchers modified the 
aspartic acid of the cross-linker with a photolabile o-nitrobenzyl ester moiety to protect the 
peptide form degradation. In the optimum condition with UV radiation for 40 s, the 
photolabile moiety dissociated from the peptide linker and exposed the cross-linker for 
caspase-3 degradation, releasing the encapsulated caspase-3. Using the same strategy but 
with caspase-3 degrading the capsule from outside, a fluorescent single protein nanocapsule 
for caspase-3 activity assay was developed.[89] Based on these work, Biswas et al. used a 
bisacrylated peptide linker that contained the peptide substrate of furin, an endoprotease 
ubiquitously expressed in many mammalian cells.[90] Instead of releasing the encapsulate 
protein from within, furin can degrade the capsule and release the cargo protein externally to 
deliver them to their corresponding nuclear and cytosol location. Researchers from the same 
group also developed a redox responsive cross-linker that contained a disulfide bond.[29] 
Anticancer proteins, whether monomeric caspase-3 (30 KDa) [29] or apoptin complex (2.4 
MDa)[19], were successfully delivered intracellularly, where the high GSH concentration 
triggered the capsule degradation and protein release. Intracellular trafficking of rhodomine-
labeled apoptin encapsulated in the redox responsive nanocapsule by CLSM analysis 
Sun et al. Page 10













showed that the delivered apoptin localized only in the nucleus of cancer cell to induce 
apoptosis but remained in the cytosol of normal cells.
In addition to covalent cross-linking, ionic cross-linkers that binds oppositely charged 
polymers were also used in preparing protein loaded nanoparticles. By adding negatively 
charged cross-linker sodium tripolyphosphate to a chitosan solution containing OVA or 
melanocyte-associated antigen gp100 protein, Li et al. obtained antigen loaded chitosan 
nanoparticles.[91] The chitosan nanoparticle has a size of 258 ± 15 nm and zeta potential of 
27.6 ± 4.7 mV when loaded with OVA. The OVA loaded chitosan nanoparticle induced 
significant higher anti-OVA IgG than OVA solution in both intact and stratum corneum-
removed skin. In BALB/c mice models inoculated with B16BL6 cells, chitosan nanoparticle 
loaded with gp100 increased the survival rate from 20% to 80 % after 20 days of 
inoculation.
4.3 Emulsion based encapsulation
In emulsion polymerization based encapsulation, the particles are morphed by interfacial 
repulsion between the aqueous phase and the organic phase. Various bio-degradable 
polymeric carriers for functional protein delivery were prepared by emulsion techniques. 
Noh et al. prepared a theranostic PLGA nanoparticle delivering both antigen (OVA) and 
bimodal imaging probes (indocyanine green (ICG) and iron oxide).[92] The multifunctional 
polymeric nanoparticle (MPN) can trace the migrations of MPN internalized dendritic cells 
into lymph nodes. The MPN was prepared by the double-emulsion solvent extraction 
method, in which the aqueous ICG-OVA solution was homogenized in an organic phase of 
methylene chloride containing PLGA and iron oxide to obtain a water in oil (w/o) emulsion. 
Then the w/o emulsion was emulsified in a second aqueous phase (PVA solution) by 
sonication to produce a w/o/w emulsion followed by solvent evaporation to harden the 
PLGA particles. The MPN has a smooth surface morphology with an average diameter of 
189.57 ± 32.89 nm and zeta potential around - 23 mV. Study of MPN-OVA intracellular 
trafficking in dendritic cell by fluorescent microscope showed that FITC labeled OVA can be 
detected in the lysosome and co-localization of FITC-OVA with ICG in the cytosol can be 
observed. Lymphocytes isolated from the treated mice showed high cytotoxicity towards 
EG7-OVA cells, while low cytotoxic lymphocyte was detected with mice treated with 
soluble OVA or human serum albumin loaded MPN. Similarly, Sarti et al. encapsulated OVA 
and a immunostimulant monophosphoryl lipid A (MPLA) in a 320 nm PLGA nanoparticle 
for oral antigen delivery.[93] In addition to PLGA nanoparticles, PLGA microparticles can 
also be prepared via double emulsion. Kim et al. encapsulated PEGylated TRAIL in PLGA 
microsphere for sustained local release at tumor sites.[40] The PEG-OVA loaded microsphere 
has a size of 12.9 ± 1.98 μm. PEGylation at N-terminal of TRAIL significantly enhanced its 
encapsulation efficiency as well as anticancer efficiency possibly due to the shielding effect 
of PEG on protein surface. In vivo study with BALB/c athymic mice bearing HCT 116 
tumors showed 78.3 % tumor suppression with PEGylated TRAIL microsphere while only 
25.9 % tumor suppression was observed with TRAIL microsphere at 24 days. In stead of 
double emulsion, Azagarsamy et al. demonstrated a photo-degradable protein delivery 
carrier synthesized by inverse emulsion. [94] The cargo protein was dissolved in the aqueous 
phase containing monomer hydroxyethylacrylate (HEA) and a light sensitive cross-linker. 
Sun et al. Page 11













Followed by dispersion in the organic phase of n-heptane containing surfactant Brij 30, the 
polymerization was initiated by adding radicals into the organic phase. The obtained 25-40 
nm nonoparticles showed continuous decrease in size upon light irradiation (λ=365 nm).
4.4 Dendrimers
Unlike linear polymers, dendrimers are hyperbranched polymers characteristic for their 
monodispersity, nanometric size range, controllable architecture and surface groups. 
Dendrimers generally contain three distinct domains: a multifunctional core, branched 
repeats emanating from the core with radically concentric layers called “generations” and 
surface functional groups at the terminal of the branches.[95] Sheng et al. developed a 
mannosylated polyamidoamine (PAMAM) dendrimer for OVA delivery.[96] A generation 4 
cystamine dendrimer containing 64 amine sites was mannosylated with 30-fold molar excess 
of activated mannose. Reducing the dendrimer core exposed a thiol group for OVA 
conjugation. Mannosylation enhanced the uptake efficiency of the dendrimer loading OVA 
via its interaction with mannose receptors on antigen presenting cell surface. The 
Mannosylated dendrimer loading OVA (MDO) not only enhanced antigen presentation but 
also induced dendritic cell maturation. Mice pre-immunized with MDO showed high 
resistance to B16-OVA tumor cells with delayed onset, slower kinetics of growth and higher 
survival rate. Ng et al. conceived a reversible pH responsive protein delivery strategy using 
second generation PAMAM dendritic shell to coat the surface of therapeutic proteins 
(Figure 6).[97] After modifying lysine residues on protein surface with 4-
carboxyphenylboronic acid and modifying PAMAM dendron core with ethynyl hydroxamic 
acid, the dendrons self assembled onto protein surfaces via an acid labile boronic acid/salicyl 
hydroxamate ligation. Enzymatic activities were sterically blocked by the branched dendrons 
with high volume weight ratio at physiological pH (pH 7.4). The drendritic shell facilitated 
clathrin-dependent endocytosis of the cargo protein and escaped the endosome by proton 
sponge effect. Degradation of the shell under acidic environment (pH 5.0) can restore 
enzyme activities by > 90 %. In stead of directly ligating proteins onto dendrimers, Ng et al. 
also developed a multidomain protein delivery system that used protein streptavidin as the 
multi-functional core to assemble biotinylated proteins (p53 or cytochrome c) and second 
generation PAMAM dendrons.[98] The PAMAM dendrons presented positively charged 
surfaces for enhanced cellular uptake and increased the size of unmodified streptavidin from 
~ 4 nm to ~ 5 nm. Further assembly of biotinylated p53 or cytochrome c increased the sizes 
further to 7.53±1.35 nm and 7.06±1.15 nm, respectivley. The uptake efficiency of the 
nanocomplex is considerably affected by the molar ratio of PAMAM dendron to the loaded 
protein, 40-fold molar excess of the dendron achieved the maximum p53 delivery efficiency 
to the cytosol of HeLa cells via endocytosis. P53 delivered into SaOS cells by the 
nanocomplex activated the apoptosis pathways and upregulated caspase −3, −7 activities.
4.5 Polymersome
Similar to liposome, polymersomes are hollow spheres with an aqueous core enclosed by 
membranes. The hydrophobic middle part of the membrane can integrate hydrophobic drugs 
while the hydrophilic core can encapsulate water soluble drugs, nucleotides or proteins. 
Instead of lipids, polymersomes are made of amphiphilic block copolymers that can be 
manipulated with different stability and permeability to control drug release.[99] Based on 
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the link between an oxidative endosomal environment in dendritic cells and their antigen 
cross-presentation capability, Scott et al. applied a 100 nm oxidation-sensitive polymersome 
self-assembled from a block copolymer poly (ethylene glycol)-bl-poly(propylene sulfide) 
(PEG-PPS) to deliver OVA and small molecule adjuvants.[100] Oxidation of PPS into 
sulfoxide restructured the polymersome vesicle into micelles, releasing the encapsulated 
cargos, and the protein release kinetics were affected by oxidative stress. While no release 
was detected with 0.1% hydrogen peroxide within 48 h, 75 % of the encapsulated protein 
was released within 24 h at the presence of 0.5% hydrogen peroxide. The dissociated 
amphiphile fragments permeabilized endosome membrane to allow endosomal escape and 
the resulting micelle possessed a hydrodynamic size of 50 nm, which was small enough to 
be cleared out of the body by kidney.
In contrast to using the oxidative stress within dendritic cells, Wang et al. utilized the 
reductive endosomal environment of Hepatoma cells and designed a redox responsive 
chimeric polymersome.[101] Three polymeric blocks, the hydrophilic PEG, the hydrophobic 
poly(ε-caprolactone) (PCL) and the positively charged poly(2-(diethylamino)ethyl meth-
acrylate) (PDEA) were assembled with different functional moieties, such as galactose (Gal) 
and disulfide bonds (SS), into PEG-PCL-PDEA, Gal-PEG-PCL, and PEG-SS-PCL. With 
PEG-PCL-PDEA as the polymersome backbone, Gal-PEG-PCL and PEG-SS-PCL were 
intercalated into the asymmetric polymersome to introduce a targeting ligand and a 
reduction responsive moiety, respectively. With positively charged PDEA locating in the 
interior of the polymersome, high protein loading capacity was achieved via electrostatic and 
hydrogen bond interactions. Protein release was significantly accelerated in the presence of 
10 mM GSH, with 77.2 % and 22.1% of FITC-BSA released from the polymersome (50 % 
PES-SS-PLC) at 37 °C within 12 h in the presence and absence of GSH, respectively. 
Granzyme B delivered into HepG2 cells using this chimeric polymersome showed a 
markedly low IC50 of 2.7 nM, which is comparable to microinjected granzyme B into 
MCF-7 cells.
In addition to single stimulus responsive polymersomes, dual stimuli responsive 
polymersomes were also developed for intracellular protein delivery. Cheng et al. developed 
a reduction and temperature dual-responsive polymersome for intracellular protein 
delivery.[102] Thermo-sensitive triblock copolymes made of PEG, poly (acrylic acid) (PAA) 
and poly N-Isopropylacrylamide (PNIPAM) were synthesized with lower critical solution 
temperatures (LCST) of 38-39 °C under physiological conditions. The triblock copolymer 
PEG-PAA-PNIPAM readily assembled into stable polymersome at elevated temperatures, 
which was further crosslinked with cystamine to make it stable at physiological temperature. 
Exposure of the polymersome to both physiological temperature and highly reducing 
environment simultaneously triggered the release of the encapsulated OVA or cytochrome c.
4.6 Micelles
Self-assembled from amphiphilic block copolymers but without the aqueous core as in 
polymersomes, micelles also have core-shell structures that can be applied in drug 
delivery.[103] Lee et al. applied a polyionic complex (PIC) micelles assembled from a block 
copolymer with a neutral block (PEG) and a positively charged poly amino acid block to 
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deliver positively charged protein cytochrome c.[104] To enhanced the stability of PIC 
micelles for protein delivery, lysine residues of cytochrome c was modified with citraconic 
amide and cis-aconitic amide to convert the surface charge from negative to positive as well 
as increased charge density. Moreover, pH sensitivity of the formulation was endowed by the 
pH labile amide groups on the surface of cytochrome c, which could shed from cytochrome 
c and expose the negatively charged surface to destabilize the micelle (Figure 7). Ren et al. 
reported a pH/sugar responsive PIC core-shell micelle assembled from two block 
copolymers.[105] A neutral block (PEG) and an ionic block (negative poly-glutamic acid 
(PGlu) or positive poly-lysine (PLys)) were incorporated into the copolymers to assemble 
the micelle through electrostatic interactions. Phenylboronic acid and catechol were 
incorporated into the PGlu and PLys blocks, respectively, to crosslink the ionic core by 
boronate ester bonds. The crosslinking reduced the size of micelle from 172.5 nm to 85.3 
nm, and increased the zeta potential from −0.21 ± 1.56 mV to 2.32 ± 1.68 mV (35% 
crosslinking ratio). Proteins with either positive or negative charges were successfully 
encapsulated in the micelle core via electrostatic interactions in neutral aqueous conditions. 
Due to the dual responsiveness of the boronic ester bond to competing diols or acidic pH, 
cross-linked PIC micelle was stable under physiological conditions but disassembled in the 
presence of excess fructose or endosomal pH to release the loaded cargo. Cytochrome c 
loaded in this cross-linked PIC micelle showed minimal release (<20%) in a stimuli-free 
environment within 24 h. The presence of 50 mg/mL fructose, but not glucose, induced the 
release to ~50 % during the same time, which was further augmented by changing the 
environment pH from 7.4 to 5.0. Uptake of the cytochrome c loaded micelle could be 
observed in HepG2 cells within 4 h and it induced much higher apoptosis (17.55%) than free 
cytochrome c (6.66%) within 24 h.
Unlike the ionic core formed by electrostatic interaction, Keller et al. synthesized a pH 
responsive micelle with a core formed by hydrophobic interactions.[106] The amphiphilic 
copolymer was synthesized by Reversible Addition-Fragmentation Chain Transfer (RAFT) 
polymerization with a hydrophilic block containing N-(2-hydroxypropyl) methacrylamide to 
form the micelle shell and a hydrophobic block containing dimethylaminoethyl 
methacrylate, propylacrylic acid, and butyl methacrylate to form the core. Pyridyl disulfide 
groups were incorporated into the hydrophilic shell for reversible antigen conjugation while 
the pH responsive core can disintegrate the 30 nm micelle into < 10 nm particles at pH 5.8 
and destabilize endosomal membrane for endosomal escape. In vitro tests with dendritic cell 
2.4 showed that OVA conjugated to the micelle surface generated 67-fold higher antigen 
than soluble OVA within 4 h after uptake. C57Bl/6 mice subcutaneously immunized with 
OVA conjugated micelle showed that the micelles were drained into the lymph nodes and 
preferentially associated with dendritic cells after 24 h of injection, activating OVA-specific 
CD8+ T cells.
5. Biomacromolecules for anticancer protein delivery
5.1 DNA nanostructure
With superior biocompatibility and programmability, DNA nanostructures, from simple 
linear chains to complex three dimensional structures, were explored as carriers for 
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therapeutic protein delivery. Zhang et al. reported a multivalent polymeric DNA scaffold 
synthesized by rolling circle amplification for antibody conjugation.[107] With a circular 
ssDNA as template, long chain ssDNA containing repeated sequences complementary to the 
template was amplified using a oligonucleotide primer and phi 29 DNA polymerase. Biotin 
modified dUTP was incorporated into the ssDNA product for complexing with biotinylated 
anti-CD 20 via NeutrAvidin as the adaptor. This cluster of anti-CD20 ligated cancer cell 
surface CD20, initiating a signaling cascade to induce apoptosis. The anti-CD20 cluster 
showed significantly higher anticancer activity towards B-cell cancer cells than soluble anti-
CD20.
Liu et al. developed a protein antigen delivery platform using a DNA tetrahedron based on 
Watson-Crick base pairing.[108] DNA oligos with precisely designed complementary and 
linker sequences were hybridized via temperature dependent DNA denaturation and 
annealing. With a biotin moiety incorporated into one of the oligos, streptavidin was 
conjugated into the tetrahedron as a model antigen together with a oligonucleotide adjuvant 
CpG. The cellular internalization efficiency of DNA tetrahedron was tested in mouse macro-
phage-like cell line RAW 264.7, which showed co-localization of the antigen loaded 
tetrahedron with lysosome within 2 h. Analysis of antibody induction efficiency of the DNA 
tetrahedron delivered antigen in a BALB/c mouse showed long term immunity responses, 
possibly due to its activation of antigen-specific memory B cells. Using a similar structure, 
Erben et al. filled the 2.6 nm central cavity of a DNA tetrahedron, which could contain a 
roughly 60 KDa globular protein, with cytochrome c (12.4 KDa) by conjugating amine 
groups on cytochrome c surface to 5’ of the DNA oligo before assembling the 
tetrahedron.[109]
Douglas et al. designed an aptamer gated DNA nanorobot for antibody delivery (Figure 
8).[110] The nanorobot was assembled by folding a 7308 bp filamentous phage derived 
ssDNA scaffold with hundreds of short DNA oligo staples into customized three 
dimensional structure. Antibodies were conjugated to the 5’ end of a 15 bp ssDNA linker for 
hybridizing onto the interior surface containing extended staples as payload binding site. 
Two of three DNA aptamer based locks, which can be opened with specific antigen keys on 
specific cell surface, were incorporated into the barrel like nanorobot simultaneously to 
control the sequester and exposure of the loaded payload. Selected combination of the 
payload antibodies and aptamer locks can regulate specific cell functionalities in targeted 
cell lines, such as inhibited aggressive natural killer cells or activated T cells.
5.2 Protein nanoparticle
Although cell membranes are impermeable to most proteins, self-assembled protein cages or 
proteins fused with a cell penetrating peptide or antibody are readily internalized by 
mammalian cells. Cell penetrating peptide (CPP), which can be classified into cationic, 
amphipathic and hydrophobic, interacts with various cell surface molecules to deliver the 
tethered protein via multiple pathways, including direct translocation through membrane 
bilayers and endocytosis.[111] Granadillo et al. used a cell penetrating and 
immunostimulatory peptide derived from the Limulus polyphemus protein (LALF32–51) to 
deliver human papillomavirus (HPV) 16 E7 antigen for cancer immunotherapy.[112] 
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Immunofluorescence microscopy with J774 murine macrophages cell line confirmed the cell 
penetrating ability of LALF32–51-E7 by the detectable fluorescence signal after incubation 
for 30 min while no signal was detected with soluble E7. C57BL/6 mice inoculated with 
TC-1 tumors showed statistically significant reduction in tumor size only with LALF32–51-
E7 vaccination but not with LALF32–51, E7 or their mixture. Essafi et al. genetically fused a 
protein transduction domain of HIV transactivating transcription factor protein (TAT) with 
transcription factor FOXO3 to treat leukemia.[113] FOXO3 could induce cell cycle arrest in 
lymphocytes but Akt-dependent phosphorylation of wild type FOXO3 excluded FOXO3 
from the nucleus and inhibited its transcriptional activity, which was avoided by mutating 
the phosphorylation sites of wild type FOXO3. The TAT fusion delivered both wild type and 
mutant FOXO3 into the cytosol of Jurkat cells but only the mutant FOXO3 was successfully 
targeted to the nucleus. Flow cytometry analysis showed that TAT fused mutant FOXO3 
induced massive cell death in Jurkat T-cell leukemia and K562 chronic myelogenous 
leukemia cells.
Antibodies can deliver cytotoxic agents, including proteins, radionuclide and small 
molecules, into malignant cells by targeting overexpressed receptors on cell surface.[114] 
Bull-Hansen et al. targeted human epidermal growth factor receptor HER2, which is 
overexpressed in 20% - 30% of breast tumors, with HER2 single-chain antibody fragment 
MH3-B1 fused type I RIP toxin gelonin (rGel).[115] Tests in four breast cancer cell lines 
with different HER2 expression levels (MDA-MB-231, BT-20, Zr-75-1 and SK-BR-3) 
showed that ~120 times more MH3-B1/rGel accumulated in HER2 high expressing cell line 
SK-BR-3 than HER2 low expressing cell line MDA-MB-231 and the IC50 was reduced by 
~1000 time in SK-BR-3 while no obvious difference in IC50 was observed between rGel and 
MH3-B1/rGel in MDA-MB-231. Despite the compelling targeting efficiency of anti-body 
conjugated proteins, lacking a cost-effective production platform hurdled its translation to 
marketplace. To solve this problem, Tran et al. used the chloroplast of green alga 
Chlamydomonas reinhardtiias instead of commonly used E. coli or CHO cells as a platform 
to express an anti-body fused exotoxin A, which can target B-cell surface receptor CD22 and 
inhibit protein translation in B-cell tumors.[116] The algae contains a single chloroplast with 
machineries like chaperons, protein disulfide isomerases and peptidylprolyl isomerases to 
fold and assemble complex eukaryotic proteins. Monomeric CD22 antibody fused exotoxin 
A synthesized by the chloroplast selectively killed CD22 expressing B cells like CA-46 and 
Ramos with IC50 of 0.246 nM and 1.39 nM, respectively, but it did not inhibit CD22 
deficient Jurkat T-cell proliferation. The authors reasoned that with algae's potential as cost-
effective source of bio-fuels, it holds great promise to function as a cost-effective platform 
for producing protein therapeutics.
Protein nanocages, such as ferritin, heat shock protein or virus capsid, are mono-dispersed 
symmetrical assemblies of a certain number of protein subunits. The highly defined structure 
and biocompatibility of protein nanocages make them promising platforms for drug 
delivery.[117] Patel et al. synthesized bacteriophage MS2 and Qβ virus like particles (VLP) 
that were symmetrical icosahedrons by cell free protein synthesis as a platform to deliver 
proteins and nucleotides.[118] Functionalized cargo molecules were covalently conjugated on 
the surface of the VLPs containing non-natural amino acids as binding site. The non-natural 
amino acids were analogous to methionine but contained terminal azide and alkyne groups 
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for click chemistry based coupling. In contrast to surface conjugated cargo loading, 
Wörsdörfer et al. encapsulated a toxic HIV protease in the void core of a protein capsid by 
directed evolution.[119] The evolved lumazine synthase self-assembled into icosahedral 
capsids, containing negatively charged residues on luminal surface to enhance its interaction 
with the positively charged guest molecules.
6. Living particles for anticancer protein delivery
6.1 Bacteria
Advances in synthetic biology have made it easy to manipulate bacteria genetics to construct 
nano-/micro- scale factories producing therapeutic molecules. Advantages like targeting 
specificity, self-propulsion and environment sensing capabilities made bacteria a promising 
carrier for cancer therapy.[120]
Zhu et al. utilized rod shaped E. coli (1-3 μm in length and 0.5μm in diameter) as carrier for 
controlled protein delivery.[121] The non-invasive E. coli strain BL21, a model protein 
expression host in the field of biotechnology, was used to deliver exotoxin A by expressing it 
from plasmid pET28a. To facilitate protein release, a red-emissive cationic polyelectrolyte 
was coated onto BL21 (BL21 capsule) together with pretreating BL21 with membrane 
disrupting peptide antibiotic polymyxin B. Polyelectrolyte coating collapsed the smooth 
surface of BL21 and confocal laser scanning microscopy confirmed that the BL21 capsule 
was internalized by A 498 human kidney carcinoma cells and located around the nucleus. 
MTT assay with A498 cells showed that only the exotoxin A expressing BL21 capsule 
caused severe cell death (~ 50%) within 48 h while the empty BL21 kept a 100 % cell 
viability and empty BL21 capsule caused only slight cell damage (> 80 % viability). In 
addition, the author noted that the coated polyelectrolyte can also generate reactive oxygen 
species upon light triggering, making the polyelectrolyte coated BL21 a versatile vector for 
tumor destruction.
Instead of using cell membrane disrupting agents to facilitate protein release, Gouëllec et al. 
utilized the needle-like type III secretion system (T3SS) of Pseudomonas aeruginosa (P. 
aeruginosa) for antigen delivery.[122] P. aeruginosa was genetically engineered for attenuated 
virulence by deleting the genes coding exonucleotidse A and B subunits, which disabled P. 
aeruginosa to repair random DNA cross-linkings upon photochemical treatment, leaving P. 
aeruginosa in a “killed but metabolically active” (KBMA) state without the ability to 
proliferate. Expression of the T3SS activator is controlled with an isopropyl β-d-1-
thiogalactopyranoside-inducible promoter and major secreted exotoxins from the T3SS were 
deleted. To test the ability of KBMA P. aeruginosa T3SS to deliver functional proteins into 
eukaryotic cells, a signal peptide derived from exotoxin S (S54) was fused with β-lactamase 
and detectable β-lactamase activity in HL60 cells can be observed after incubating HL60 
cells with KBMA P. aeruginosa for 3 h. Toxicity of the P. aeruginosa vaccine towards 
C57BL/6J mice showed that KBMA P. aeruginosa secreting antigen S54-OVA caused no 
mouse death while the live P. aeruginosa secreting S54-OVA killed all the mice within 24 h. 
KBMA P. aeruginosa secreting S54-OVA successfully disseminates into lymph nodes to 
activate dendritic cells for presenting antigens to CD8+ T cells, achieving efficient tumor 
protection in mice model xenografted with B16-OVA cells.
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In addition to bacteria, human derived cell lines were also developed as protein carriers with 
reduced concern about unexpected toxicity or immunogenicity as in bacterial carriers. Kown 
et al. utilized the long life-span of erythrocytes and translocated L-asparaginase into red 
blood cells (RBCs) via a protamine-asparaginase fusion to treat acute lymphoblastic 
leukemia.[123] The asparaginase loaded RBCs retained their native morphology as observed 
by scanning electron microscopy and shielded asparaginase from proteolytic degradation. In 
a lymphoma cell L5178Y bearing mice model, mice treated with asparaginase containing 
RBC elongated the mice survival time by ~44% as compared to the saline control group. 
Mitchell et al. coated leukocytes with TRAIL through E-selectin based adhesion to mimic 
natural killer cells for killing circulating cancer cells (CTC) in the bloodstream (Figure 
9).[32] Leukocytes share similar migration characteristics with CTC in the near-wall region 
of bloodstreams due to the sialylated carbohydrate ligands presented on their surfaces that 
can interact with selectins on endothelial cell walls. The authors reasoned that 
functionalizing leukocytes with TRAIL could utilize the number advantage of leukocytes 
(leukocyte/CTC number ratio at ~ 1×106) to squeeze TRAIL onto the surface of sparse CTC 
(1-100 cells/mL) during migration. TRAIL was coated onto blood leukocytes via a liposome 
displaying both E-selectin and TRAIL under shear flow and the adhesion efficiency in 
leukocyte subpopulations were directly related with their E-selectin ligand expression levels. 
Liposome containing E-selectin injected into mice blood circulation readily adsorped onto 
leukocytes, the injection of COLO 205 cells 30 min after E-selectin liposome or E-selectin/
TRAIL liposome administration resulted in ~130,000 and <2000 living COLO 205 cells, 
respectively, confirming the anticancer effect of TRAIL coated leukocytes. Instead of using 
a liposome-assisted TRAIL displaying technique, Barti-Juhasz genetically engineered bone 
marrow derived mesenchymal stem/stromal cells (MSC) to express and secrete TRAIL from 
a transduced pORF-TRAIL plasmid.[124] In vitro tests showed that MSC-TRAIL inhibited 
the growth of RD rhabdomyosarcoma cells by 85%, while a MSC expressing GFP showed 
no significant inhibition.
The migratory ability and tumor tropism of stem cells make them attractive carriers for 
targeted cancer therapeutic delivery. Neural stem cells (NSCs), which can home in on 
tumors inside or outside the brain, was utilized by Zhu et al. to deliver a fusogenic 
membrane glycoprotein that can induce cell-to-cell fusion based cell death.[125] The 
vesicular stomatitis virus glycoprotein (VSV-G) is one of the fusogenic glycoproteins that 
mediates cell fusion at acid environment (pH 4.8 - pH 6.4). By introducing a point mutation 
H162R, the authors enhanced the working pH of VSV-G to pH 6.8, which matched 
extracellular pH at tumor tissue (pH 6.5 - pH 7.1) but below the pH of normal tissue (pH 7.3 
- pH 7.4), leading to higher specificity towards tumor tissues. Immunofluorescence staining 
showed that both VSV-G wild type (WT) and H162R expressed from a recombinant plasmid 
in NSCs were successfully exported to cell surface. Incubating mouse 4T1 breast cancer 
cells with NSCs expressing WT or H162R at different pH shock conditions showed that no 
cell fusion occurred at pH 7.4 for both WT and H162R while cell fusion occurred at pH 6.8 
for H162R but not WT. Combination of the pH selectivity of H162R and tumor tropism of 
NSCs showed enhanced specificity and tumor suppression effects in 4T1 cell-bearing mice 
via systemic administration, enhancing the median survival time from 17 days in the PBS 
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group to 24 days, while no significant off-target damage was detected in non-targeted 
organs.
7. Summary and outlook
Anticancer proteins, whether bind extracellular receptors or target intracellular machineries 
hold vast promise for cancer treatment. Substantial achievements have been made in 
tailoring carriers to protect fragile proteins against detrimental physiological environments 
and deliver the cargo proteins to their functional sites. As summarized in Table 1, various 
types of carriers, from inorganic particles to organic polymer capsules, and from synthetic 
particles to whole living cells, were developed to convoy therapeutic proteins to their 
targeting loci through local or systemic administration. Abundant experiences about efficient 
protein loading, uptake, release and targeting were accumulated. Despite these 
accomplishments, anticancer protein delivery is still in its infancy with only a few 
formulations made it through clinical trials and finally entered the market.[126]
Further optimizations of the carriers are needed with respect to their stability, 
biocompatibility and targeting efficiency. Combining the innate advantages of different 
carriers is a facile approach to develop more bio-compatible carriers. For example, to 
overcome the poor degradability of gold nanoparticles, degradable DNA can be incorporated 
into a gold nanoparticle matrix for enhanced elimination.[37] To improve tumor targeting 
efficiency of a polymeric nanoparticle, a tumor cell membrane derived lipid shell was coated 
onto the nanoparticle to formulate a biomimetic particle that can induce homotypic binding 
based targeting as well as cancer specific immune responses.[127] The concept of developing 
biomimetic carriers by using synthetic particles to mimic the functions of natural protein 
delivery carriers, such as viruses, bacteria, eukaryotic cells or cell compartments, is an 
effective strategy to deliver anticancer proteins.[43] Combination therapy is another effective 
cancer killing strategy by programing different anticancer therapeutics, such as protein, 
siRNA or small molecule drugs, inside one single carrier, activating different tumor 
inhibition pathways simultaneously.[10, 128, 129] In addition, adding stimuli responsiveness to 
protein carriers can reduce unexpected cytotoxicity. Off-target cytotoxicity caused by 
passive protein release can be reduced by spatial- temporal- and dosage- controllable drug 
release profiles. Endogenous characteristics of tumor tissue microenvironment (such as acid 
pH[130], high GSH concentration[131], high ATP concentration[132, 133] and overexpressed 
proteases[90]) and controllable external signals (such as temperature[134], electric/magnetic 
field[135, 136], ultrasound[137] or light[138]) can all be harnessed to achieve controlled protein 
release.[38] Although current protein delivery platforms mostly target primary tumors, with 
increasing understanding of tumor physiology carriers that combat metastatic tumors, which 
are generally considered incurable, at each stage of the metastasis can be expected.[139] 
Moreover, proteins can be utilized as versatile carriers for various kinds of drugs such as 
siRNA[140] or small molecule drugs[132, 133] for anticancer therapy. Drug loading and release 
profiles can be adjusted by tuning the surface properties of protein [141].
Last but no least, the added functionalities to protein delivery carriers, such as targeting 
ligand, stimuli sensors or other auxiliary moieties, for improved protein delivery efficacy, 
inevitably increase the synthesis complexity and cost of these formulations. The cost/benefit 
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ratio of adding these functions need to be considered for more competitive drugs in the 
future market.[142]
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Schematic of different carriers for anticancer protein delivery.
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Multiwall carbon nanotube (MWCNT) mediated intracellular delivery of ricin A-chain 
(RTA) through clathrin-mediated endocytosis by Kong and coworkers. (A) Confocal 
fluorescent image of endoplasmatic reticulum. (B) Confocal fluorescent image of EGFP-
RTA. (C) Co-localization of EGFP-RTA with endoplasmatic reticulum. (D) TEM image of 
MWCNT localized in endosome and (E) Magnification of the white rectangular in D shows 
individual MWCNTs. (F) Confocal image of cells incubated with MWCNT-RTA conjugate 
and (G) Control confocal image of cells incubated with soluble RTA. Reprinted with 
permission from ref.[55]. Copyright 2010 American Chemical Society.
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Intracellular delivery of caspase 3 using nanoparticle stabilized capsules (NPSC) by Rotello 
and coworkers. (A) Schematic of the preparation of protein-NPSC complex and mechanism 
for protein delivery. (B) Delivery of caspase 3 into the cytosol of HeLa cells by caspase 3-
NPSC complex. Copyright 2013 American Chemical Society.
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Sequential delivery of TRAIL and Doxorubicin (DOX) to specific cellular locus using a 
polymeric gel coated liposome (Gelipo) by Gu and coworkers.[10] (A) Schematic of 
sequential deliveries of TRAIL to cell membrane and DOX to nucleus. I, TRAIL/DOX-
Gelipo accumulated at tumor site by passive and active targeting. II, Degradation of the 
polymeric shell (HA) by overexpressed HAase at tumor site. IIIa, TRAIL was released and 
binds to the death receptors on cell surface. IIIb and IIIc, TRAIL induced apoptosis 
signaling and cell death. IVa and IVb, Liposome uptake mediated by surface modified R8H3 
ligand. IVc and IVd, Endosome escape and release Dox into nucleus. IVe, Dox induced cell 
death. (B) Hydrodynamic size and TEM image of TRAIL/DOX-Gelipo. Scale bar 200 nm. 
(C) Mice bearing MDA-MB-231 xenograft treated with (a) Saline, (b) DOX solution, (c) 
DOX-Gelipo and (d) TRAIL/Dox-Gelipo. Reprinted with permission from ref.[10]. 
Copyright 2014 Wiley-VCH.
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Self-degradable single protein nano-capsule for delivering caspase 3 by Tang and coworkers. 
(A) Schematic diagram of the in situ polymerization process. (B) TEM characterization of 
freshly prepared caspase-3 capsule and (C) TEM image of self degradable caspase-3 capsule 
after incubation at 37 °C for 12h . (D) Bright field image of HeLa cells treated with saline, 
self-degradable caspase-3 capsule, non-degradable caspase-3 capsule and naked caspase-3 
for 24 h. Reproduced with permission from ref.[88]. Copyright 2009 American Chemical 
Society.
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Coating pH responsive dendritic shell on protein surface for intracellular delivery by Weil 
and coworkers. (A) Schematic diagram of the pH responsive dendritic coating and de-
coating on protein surface. (B) Colocalization of dendronized papain and A549 cell 
lysosome. (C) Structure of the dendron. Reprinted with permission from ref.[97]. Copyright 
2013 Wiley-VCH.
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Charge-conversional PIC micelles for delivering cytochrome c by Kataoka and Coworkers. 
Schematic of the preparation of the PIC micelle. Copyright 2009 Wiley-VCH.
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Deliver antibodies with logic aptamer-gated nanorobot by Douglas and coworkers. (A) 
Schematic view the nanorobot in closed and open status. (B) Mechanism of the aptamer 
guided lock and open. Aptamer strand (blue), complementary strand to the aptamer (orange) 
and antigen (red). (C) TEM characterization of the open and close of nanorobot (left lane), 
nanorobot loaded with 5 nm gold nanoparticle (middle lane) and nanorobot loaded with 
antigen (right lane). Reprinted with permission from ref.[110]. Copyright 2012 Science.
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Coating TRAIL on leukocyte surface to target circulating tumor cells in bloodstream by 
King and coworkers. (A) Schematic diagram of liposome assisted coating of leukocytes with 
TRAIL and tumor targeting. (B) Schematic diagram of synthesizing liposomes containing 
TRAIL and E-selectin. (C) Confocal image of TRAIL coated leukocytes. Reproduced with 
permission from ref.[32]. Copyright 2014 PNAS.
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Table 1
Summary of recent anticancer protein delivery carriers.
Types of carrier Properties Therapeutic proteins cell lines ref





Caco-2 cells, HeLa, 
HepG2 L929 cells
[47-49]
PEGylated graphene oxide 200nm width, 3.6 
nm thickness, 
negatively charged
RNAse, proteinkinase A HeLa and MCF-7 [58]
Multiwalled carbon nanotubes length 1-5μm, 
diameter 15-50 nm
Caspase-3, ricin A chain 
protein (RTA), anti-HER2
MG-63, L-929, 
HL7702, MCF-7, HeLa 
and COS-7
[51, 54, 55]
Mesoporous silica nanoparticles diameter 90-150 
nm, pore size 
3.6-4.5 nm
OVA, cytochrome c HeLa [60, 62]
Gold nanoparticles 5 -140 nm Caspase 3, OVA, extra 
domain B (EDB) of 
fibronectin-OVA257-269
Hela CCD 1106 KERTr, 
DC2.4
[65-67]
Lipid Liposome ~60-180 nm OVA, TRAIL, anti-EGFR MDA-MB-231, 
U87MG, colo 205, 
Jurkat, DC2.4
[10, 24, 71, 72, 76]
Exosome/vescicle 30-160 nm OVA, cytosine deaminase 
(CD) fused to uracil 
phosphoribosyltransferase 




Lewis lung carcinoma 
(LLC)
[79-81]
polymer PEGylation TRAIL Jurkat [84]
PEI conjugation p53 Saos-2 [85]
Polymalic acid conjugation 27 nm Interleukin-2 fused with 
anti-HER2/neu
D2F2,BT-474,SK-BR-3, [87]
Single protein capsules 9 nm - 36nm, 
positively charged
Klf4, caspase-3, apoptin MDA-MB-231, HeLa, 
MCF-7, U-87 MG
[19, 29, 88, 90]
Crosslinked chitosan nanoparticle ~258 nm, 
positively charged
OVA, gp100 B16BL6 [91]
PLGA particles by double 
emulsion
200 nm - 13μm, 
negatively charged
TRAIL, OVA HCT 116, EG7-OVA [40, 92, 93]
Polyamidoamine based dendrimer ~ 7 nm OVA, p53, cytochrome c, 
trypsin, papain, DNase I
B16-OVA, HeLa, A549, 
SaOS
[96-98]
polymersome 100 nm -200 nm OVA, cytochrome c, 
granzyme B
DC, CD8+ T cells, 
HepG2, HeLa and 
MCF-7 cells
[100-102]
polymeric micelle 25-85 nm Cytochrome c, OVA HepG2, MCF7, DC 2.4 [105, 106]
Biomacromolecules Linear DNA conjugation Negatively charged Anti-CD-20 CCRF-CEM, Jurkat, 
and Ramos cells
[107]
DNA nanostructure Negatively charged Streptavidin, cytochrome 
c, anti-(HLA)–A/B/C 
anti- CD33, anti- 
CDw328 Fab' fragments, 
anti- flagellin Fab'
RAW 264.7, Ramos, 
Kasumi-1, NKL
[108-110]
Cell penetrating peptide 
conjugation
FOXO3 mutant, human 
papillomavirus (HPV) 16 
E7 antigen
Jurkat, Raji, RPMI 
8866, SKW6.4, U937 
and K562, EHEB, H-2b, 
TC-1, J774, CRL-1550
[112, 113]
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Types of carrier Properties Therapeutic proteins cell lines ref
CA-46, Ramos, and 
Jurkat cells




Cell Bacteria based human cell based 1-3 μm β-lactamase (Bla), OVA, 
exotoxin A
HL60, B16-OVA, A498 [121, 122]
L-Asparaginase, TRAIL, 
stomatitis virus glyco- 
protein (VSV-G) H162R
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